Omniscient Neurotechnology vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omniscient Neurotechnology (o8t) is the pioneer of clinical connectomics with its FDA-cleared Quicktome brain mapping platform; raised up to $36M Series D led by NRFC ($20M); partnered with Jacobs Institute in 2025.
About
Omniscient Neurotechnology (branded as o8t) is an Australian medical technology company founded in 2019 and headquartered in Sydney. Omniscient is the global pioneer of clinical connectomics — the application of brain network science to patient care. Its flagship product, Quicktome, is the world''s first FDA-cleared medical device to generate detailed maps of brain networks from standard MRI scans using artificial intelligence and machine learning. Neurosurgeons use Quicktome before life-changing brain surgeries to visualize critical functional networks (motor, language, vision, memory) and plan surgical approaches that minimize neurological damage.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.